The following corporate finance-related stories were reported by media on Thursday: * Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to three people familiar with the matter.* About seven bidders are lining up for Telediffusion de France's (TDF) domestic business and lenders are preparing debt packages of more than 2 billion euros ($2.7 billion) for a deal worth about 4 billion euros, people familiar with the matter said.
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Shares of AMGN traded higher by 6.82% or $7.18/share to $112.40. In the past year, the shares have traded as low as $80.60 and as high as $114.95. On average, 3379480 shares of AMGN exchange hands on a given day and today's volume is recorded at 9917154.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. Shares of ONXX fell by 2.89% or $-3.81/share to $128.21. In the past year, the shares have traded as low as $66.37 and as high as $136.87. On average, 1872070 shares of ONXX exchange hands on a given day and today's volume is recorded at 6378282.
Source
